Works Cited
RET
eval
Device User Manual 81
Works Cited
Ahmadi, M, and Q Q Rodrigo. 2013. "Automatic denoising of single-trial evoked potentials."
NeuroImage:672-680.
Audo, I., M. Michaelides, A. G. Robson, M. Hawlina, V. Vaclavik, J. M. Sandbach, M. M. Neveu, C.
R. Hogg, D. M. Hunt, A. T. Moore, A. C. Bird, A. R. Webster, and G. E. Holder. 2008.
"Phenotypic variation in enhanced S-cone syndrome." Invest Ophthalmol Vis Sci 49
(5):2082-93. doi: 10.1167/iovs.05-1629.
Berson, EL. 1993. "Retinitis pigmentosa: The Friedenwald Lecture." Investigative Ophthalmology
and Visual Science 34:1659-1673.
Brigell, M. G., B. Chiang, A. Y. Maa, and C. Q. Davis. 2020. "Enhancing Risk Assessment in Patients
with Diabetic Retinopathy by Combining Measures of Retinal Function and Structure."
Transl Vis Sci Technol 9 (9):40. doi: 10.1167/tvst.9.9.40.
Centers for Disease Control and Prevention. 2011. National Diabetes Fact Sheet, 2011. edited by
US Department of Health and Human Services, Centers for Disease Control and
Prevention.
Cideciyan, A, and S Jacobson. 1996. "An alternative phototransduction model for human rod and
cone ERG a-waves: normal parameters and variation with age." Vision Res:2609-21.
Cideciyan, A. V., and S. G. Jacobson. 1993. "Negative electroretinograms in retinitis pigmentosa."
Invest Ophthalmol Vis Sci 34 (12):3253-63.
CLSI. 2008. Guideline for Defining, Establishing, and Verifying Reference Intervals in the Clinical
Laboratory; Approved Guideline—Third Edition. CLSI Document EP28-A3c. Wayne, PA:
Clinical and Laboratory Standards Institute.
Davis, C. Q., and R. Hamilton. 2021. "Reference ranges for clinical electrophysiology of vision."
Doc Ophthalmol. doi: 10.1007/s10633-021-09831-1.
Davis, C. Q., O. Kraszewska, and C. Manning. 2017. "Constant luminance (cd.s/m2) versus
constant retinal illuminance (Td.s) stimulation in flicker ERGs." Doc Ophthalmol. doi:
10.1007/s10633-017-9572-3.
Davis, M. D., M. R. Fisher, R. E. Gangnon, F. Barton, L. M. Aiello, E. Y. Chew, F. L. Ferris, 3rd, and
G. L. Knatterud. 1998. "Risk factors for high-risk proliferative diabetic retinopathy and
severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18." Invest
Ophthalmol Vis Sci 39 (2):233-52.
Degirmenci, M. F. K., S. Demirel, F. Batioglu, and E. Ozmert. 2018. "Role of a mydriasis-free, full-
field flicker ERG device in the detection of diabetic retinopathy." Doc Ophthalmol 137
(3):131-141. doi: 10.1007/s10633-018-9656-8.
FDA Advisory Committee. 2009. Sabril® (vigabatrin) for Oral Solution for Infantile Spasms.
To Next Page
Loading...
